BRAF and non-small cell lung carcinoma: In previously untreated metastatic NSCLC patients with BRAF-V600E, dabrafenib combined with trametinib achieved an ORR of 64% (95% CI, 46–79%), with 2 (6%) patients achieving a CR and 21 (58%) a PR (Planchard et al., 2017).